MA30387B1 - Inhibiteurs de la renine au traitement de l'hypertension - Google Patents

Inhibiteurs de la renine au traitement de l'hypertension

Info

Publication number
MA30387B1
MA30387B1 MA31327A MA31327A MA30387B1 MA 30387 B1 MA30387 B1 MA 30387B1 MA 31327 A MA31327 A MA 31327A MA 31327 A MA31327 A MA 31327A MA 30387 B1 MA30387 B1 MA 30387B1
Authority
MA
Morocco
Prior art keywords
methods
hypertension
treatment
renin inhibitors
interruption
Prior art date
Application number
MA31327A
Other languages
English (en)
French (fr)
Inventor
Andrew Satlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38420678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30387(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA30387B1 publication Critical patent/MA30387B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA31327A 2006-04-03 2008-10-23 Inhibiteurs de la renine au traitement de l'hypertension MA30387B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78884206P 2006-04-03 2006-04-03

Publications (1)

Publication Number Publication Date
MA30387B1 true MA30387B1 (fr) 2009-05-04

Family

ID=38420678

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31327A MA30387B1 (fr) 2006-04-03 2008-10-23 Inhibiteurs de la renine au traitement de l'hypertension

Country Status (20)

Country Link
US (1) US20090062395A1 (enExample)
EP (1) EP2004167A1 (enExample)
JP (1) JP2009532494A (enExample)
KR (1) KR20080108515A (enExample)
CN (1) CN101415413A (enExample)
AU (1) AU2007234917B2 (enExample)
BR (1) BRPI0710095A2 (enExample)
CA (1) CA2645260A1 (enExample)
CL (1) CL2007000912A1 (enExample)
IL (1) IL193905A0 (enExample)
MA (1) MA30387B1 (enExample)
MX (1) MX2008012729A (enExample)
NO (1) NO20084625L (enExample)
NZ (1) NZ571251A (enExample)
RU (1) RU2008143055A (enExample)
SG (1) SG170830A1 (enExample)
TN (1) TNSN08383A1 (enExample)
TW (1) TW200806283A (enExample)
WO (1) WO2007118023A1 (enExample)
ZA (1) ZA200807615B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN102212012A (zh) * 2010-04-12 2011-10-12 上海源力生物技术有限公司 一种合成阿利克伦的中间体及其制备方法
EP2768971A1 (en) 2011-10-20 2014-08-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the detection and the treatment of cardiac remodeling
AU2020259450A1 (en) * 2019-04-18 2021-11-18 EyePoint Pharmaceuticals, Inc. Methods of treating hypertension with activators of Tie-2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659065A (en) * 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5606078A (en) * 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
JP2005537822A (ja) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト 有機化合物の使用
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
WO2005037317A2 (en) * 2003-10-17 2005-04-28 Cornell Research Foundation, Inc. Mast cell-derived renin
MY148773A (en) * 2004-03-17 2013-05-31 Novartis Ag Galenic formulations of organic compounds
ES2310293T3 (es) * 2004-09-27 2009-01-01 Pantarhei Bioscience B.V. Tratamiento o prevencion de sangrados no programados en mujeres bajo medicacion que contiene progestogeno.

Also Published As

Publication number Publication date
US20090062395A1 (en) 2009-03-05
MX2008012729A (es) 2008-10-14
AU2007234917A1 (en) 2007-10-18
NO20084625L (no) 2008-11-03
IL193905A0 (en) 2009-08-03
EP2004167A1 (en) 2008-12-24
CL2007000912A1 (es) 2008-03-14
TW200806283A (en) 2008-02-01
JP2009532494A (ja) 2009-09-10
KR20080108515A (ko) 2008-12-15
SG170830A1 (en) 2011-05-30
BRPI0710095A2 (pt) 2011-08-02
WO2007118023A1 (en) 2007-10-18
AU2007234917B2 (en) 2011-05-12
CA2645260A1 (en) 2007-10-18
NZ571251A (en) 2011-12-22
ZA200807615B (en) 2009-10-28
TNSN08383A1 (en) 2009-12-29
CN101415413A (zh) 2009-04-22
RU2008143055A (ru) 2010-05-10

Similar Documents

Publication Publication Date Title
MX360150B (es) Antagonista del receptor de angiotensina ii para la prevencion o el tratamiento de enfermedades generalizadas en gatos.
ECSP077397A (es) Preparación y uso de derivados de ácido bifenil-4-il-carbonilamino para el tratamiento de obesidad
MX346186B (es) Inhibidores de proteina cinasas.
MA30387B1 (fr) Inhibiteurs de la renine au traitement de l&#39;hypertension
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
WO2007067976A3 (en) Method of using il6 antagonists with proteasome inhibitors
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
MX2009004984A (es) Metodos para conservar la funcion renal utilizando inhibidores de oxidoreductasa de xantina.
WO2007128526A3 (en) Combination comprising a vegf inhibitor and a serine protease for treating neovascular diseases
MX2010008397A (es) Inhibidores del receptor de quimioquinas cxcr3.
WO2007101232A3 (en) Inhibition of jak2 as a treatment of pulmonary arterial hypertension
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA200970512A1 (ru) Лечение по поводу множественной миеломы
EA202192528A1 (ru) Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
MX2022002398A (es) Formas cristalinas de un inhibidor de cd73.
WO2008011114A3 (en) Methionine aminopeptidase-2 inhibitors and methods of use thereof
WO2007140317A3 (en) Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
WO2007056324A3 (en) Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
TN2011000459A1 (en) Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
WO2008097468A3 (en) Selective endothelin type-a antagonists
MX2007004020A (es) Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.
MA32933B1 (fr) Combinaison d&#39;inhibiteurs de hspo90 et d&#39;herceptine
EA202192237A1 (ru) Кристаллические формы ингибитора jak2
MA31003B1 (fr) Inhibiteurs de renine pour la prevention et le traitement de l&#39;hypertension chez les patients obeses